Skip to content

The Impact of a Neutral Formulated and Designed Package Insert on Nocebo-effect.

Neutral Formulated and Designed Package Insert or Only Verbal Information Compared to Package Insert According EU-directive: a Pilot Randomised Controlled Trial to Analyse the Influence on the Nocebo Effect and Non-adherence

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03428035
Acronym
NEUPANO
Enrollment
60
Registered
2018-02-09
Start date
2018-04-01
Completion date
2018-12-31
Last updated
2018-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthopedic Surgery

Keywords

Randomized controlled trial, package insert, nocebo

Brief summary

Background The nocebo effect describes the association between the expectation of negative effects, (e.g. side effects) and the actual occurrence of negative effects. Studies have shown that the nocebo effect can be influenced by (risk) communication. Till today there is no study that compares different types of information on adverse events regarding the strength of the nocebo effect. Aim The aim of this pilot randomized controlled trial is to analyse the influence of different communication types on the frequency and intensity of adverse events and adherence. To increase the relevance and applicability of the results the study intervention builds up on package inserts because these are the most widespread form of information on side effects. Methods Patients It is planned to include 60 patients in the study. Intervention * Modified package insert: simplified and focused on neutral risk perception. The representations and formulations are based on the findings from research on evidence-based patient information and risk communication. The package insert contains the same information as the statutory package insert to ensure that it complies with the legal requirements. * Verbal information about side effects: The patient is informed verbally about side effects and does not receive any package insert. Control Package insert according to EU (European Union) Directive 2001/83 / EC (European Commission) (usual package insert). Outcomes * Number of patient reported adverse events (primary outcome). * Adherence (correct initiation of therapy, correct intake amount, premature discontinuation of therapy). * Resource use (e.g. provider contacts). Type of study Monocentric, outcome assessor, three-arm, randomised controlled pilot trial.

Interventions

OTHERPackage Insert

Modified package insert of Ibuprofen given postprocedural as pain medication

Sponsors

German Research Foundation
CollaboratorOTHER
University of Witten/Herdecke
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* elective orthopaedic surgery * planned intake of ibuprofen 600 mg to treat postoperative pain * postoperative pain medication other than Ibuprofen 600 (Opioids, Opiate, Paracetamol) no longer than 1-2 days postoperative (until discharge) * at least 18 years * able to speak German * no cognitive deficits * written informed consent

Exclusion criteria

* serious comorbidity * pain medication prior to surgery * other medication with similar side effects * polytrauma * planned inpatient rehabilitation \> one week after hospital discharge

Design outcomes

Primary

MeasureTime frameDescription
Number of patient reported adverse events6-9 days after surgeryAny reported adverse events

Secondary

MeasureTime frameDescription
Adherence6-9 days after surgeryCorrect initiation of therapy, correct intake amount, premature discontinuation of therapy
Resource use6-9 days after surgerye.g. provider contacts

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026